U.S. Department of Health & Human Services      Search the NIH Website
          Virtual Tour
          Staff Directory
          En Español Site Menu Home
			
			Health Information
				Health Care Providers & Facilities
							Health Info Lines
							HealthCare.gov
							Science Education Resources
							NIH Clinical Research Trials and You
							Talking to Your DoctorMore »
					Search Health Topics
						Quick Links
						MedlinePlus Health Info
							NIH News in Health
							Wellness Toolkits
			
			Grants & Funding
				Grants Home Page
							Find Funding
							Due Dates
							How to Apply
							About Grants
							Policy & Compliance
							Grants News/Blog
							Contracts
							Loan RepaymentMore »
					Quick Links
						RePORT
							eRA Commons
							NIH Common Fund
			
			News & Events
				News Releases
							Digital Media Kits
							Media Resources
							Media Contacts
							Images and B-roll
							Events
							Social MediaMore »
					Quick Links
						NIH News in Health
							NIH Research Matters
							NIH Record
			
			Research & Training
				Medical Research Initiatives
							Science Highlights
							Science Education
							Research in NIH Labs & Clinics
							Training Opportunities
							Library Resources
							Research Resources
							Clinical Research Resources
							Safety, Regulation and GuidanceMore »
					Quick Links
						PubMed
							Stem Cell Information
							OppNet
							NIDB
							NIH Blueprint for Neuroscience Research
			
			Institutes at NIH
				List of Institutes and Centers
							NIH Office of the Director
							Directors of NIH Institutes and Centers
							NIH Institute and Center Contact InformationMore »
					Quick Links
						NCI
              	NEI
              	NHLBI
              	NHGRI
              	NIA
              	NIAAA
              	NIAID
              	NIAMS
              	NIBIB
              	NICHD
              	NIDCD
              	NIDCR
              	NIDDK
              	NIDA
              	NIEHS
              	NIGMS
              	NIMH
              	NIMHD
              	NINDS
              	NINR
              	NLM
              	CC
              	CIT
              	CSR
              	FIC
              	NCATS
              	NCCIH
			
			About NIH
				Who We Are
							What We Do
							Jobs at NIH
							Visitor Information
							Frequently Asked Questions
							Contact UsMore »
					Quick Links
						The NIH Director
							Take the Virtual Tour
							NIH...Turning Discovery Into Health®
							Impact of NIH Research
							Science, Health, and Public Trust
 You are here Home Research & Training Accelerating Medicines Partnership (AMP)
 Accelerating Medicines Partnership® (AMP®)
 Accelerating Medicines Partnership (AMP)
    
  Alzheimer’s Disease
Autoimmune and Immune-Mediated Diseases
Bespoke Gene Therapy Consortium
Common Metabolic Diseases
Heart Failure
Parkinson’s Disease
Rheumatoid Arthritis and Lupus
Schizophrenia
Type 2 Diabetes Schizophrenia On this page About Schizophrenia
			Need for New Therapies
			AMP Approach
			Accessing AMP SCZ Data
			Governance
			Budget
 Overview The Accelerating Medicines Partnership® (AMP®) program is a public-private partnership between the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and multiple public and private organizations. Managed through the Foundation for the NIH (FNIH), AMP aims to identify and validate the most promising biological targets for therapeutics. The overall aim of AMP Schizophrenia (SCZ) is to generate tools that will considerably improve success in developing early-stage interventions for patients who are at risk of developing schizophrenia. AMP SCZ marks the first AMP initiative focused on a neuropsychiatric disorder and the fifth AMP initiative overall. As part of this innovative collaborative partnership, all AMP SCZ data and analyses will be made available to the broad biomedical community through the National Institute of Mental Health (NIMH) Data Archive. About Schizophrenia Schizophrenia is a serious mental illness that is associated with significant health, social, and economic concerns. Schizophrenia is one of the 15 leading causes of disability worldwide and individuals with the disorder are at increased risk of premature death relative to the general population. In the U.S., the estimated average potential life lost for individuals with schizophrenia is 28.5 years. Schizophrenia is characterized by alterations to a person’s thoughts, feelings, and behaviors, which can include a loss of contact with reality known as psychosis. These symptoms typically emerge in adolescence or early adulthood and, if untreated, can be persistent and disabling, interfering with a person’s ability to engage in typical school, work, and social activities. Individuals with schizophrenia often experience a delay between diagnosis and the start of treatment—ranging from 1 to 3 years—which is often associated with poorer response to treatment and significantly worse long-term outcomes. Need for New Therapies Detection and intervention before psychosis develops, when individuals are at clinical high risk for psychosis, could attenuate, postpone, or even prevent the transition to psychosis and improve individuals’ clinical and functional outcomes. AMP SCZ aims to develop measures that further define early stages of risk and predict the likelihood of progression to psychosis and other clinical outcomes. Such tools will enable clinical trials to test new pharmacologic interventions that may prevent or delay the onset of psychosis. AMP SCZ partners will work toward the shared mission of discovering promising biological markers that can help identify those at risk of developing schizophrenia as early as possible, track the progression of symptoms and other clinical outcomes, including anxiety, depression, and substance use disorders, and define targets for treatment development. AMP Approach Advancing preventive interventions for schizophrenia will require a more complete understanding of the clinical and biological predictors in the early stages of the illness. AMP SCZ will harness the power of open science to accelerate the research and development process and advance promising therapies for individuals at risk of developing schizophrenia. By combining the expertise and resources of public and private partners, AMP SCZ will provide the support needed to determine which biomarkers show the greatest potential for predicting progression of the disease in clinical high-risk individuals. A core component of AMP SCZ is establishing a research network focused on individuals who are at clinical high-risk, identifying biological markers, clinical endpoints, and other measures that predict disease trajectory and outcomes for this group. Additionally, a Data Processing, Analysis, and Coordinating Center will be created to allow researchers to integrate and analyze data from new and key existing clinical high-risk cohorts, with all data and analyses made publicly available through the NIMH Data Archive. Findings from these studies will enable researchers to develop algorithms that predict the course of illness for clinical high-risk individuals, allowing for early intervention and testing of treatments that may prevent the development of schizophrenia and reduce its impact. Through rapid data sharing and integrated, collaborative research, AMP SCZ will enable proof-of-principle clinical trials to test tools and hypotheses that emerge from the initiative. Accessing AMP SCZ Data The NIMH Data Archive will provide cloud-based infrastructure to facilitate storage and analysis of AMP SCZ data. The data archive currently holds raw and derived data collected from a total of 500,000 research participants using a variety of measures, including clinical, imaging, electrophysiological, cognitive, genetic, and outcome. All AMP SCZ data stored in the archive will adhere to the NIMH Data Archive terms and conditions and the NIMH Data Sharing Policy. Specifically, participant data will be aggregated in a privacy-enabled manner and will be protected by practices that include the removal of any personally identifiable information; accredited users will be given secure, role-based access to the data. The archive includes data dictionaries to describe and enable efficient searches across the diverse types of data. The NIMH Data Archive will work with the Data Processing, Analysis, and Coordinating Center to make data analysis pipelines available to the research community. The archive, which was established in 2006, is sustained on an ongoing basis through NIMH funds. Governance The AMP SCZ steering committee (SC) is organized by the FNIH and includes representatives from each of the partner organizations. The SC operates under the direction of the overall AMP Executive Committee and is responsible for defining and maintaining the research plan, reviewing progress of the project, and providing detailed assessment of milestones for AMP SCZ. Working groups created under the direction of the AMP SCZ SC will provide detailed technical analyses of key scientific, policy, or informatics issues that arise during implementation. Budget: 5 years ($117.709 Million Total Project Funding) Disease area
			Total NIH funding ($M)
			Total Industry funding ($M)
			Total non-profit funding ($M)
			Total project funding ($M)**Schizophrenia**
			99.38
			7.5
			10.76
				(+.062 in kind)
			117.65
				(+.062 in kind) ***ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services.***
 This page last reviewed on April 5, 2023
 Related LinksAMP research efforts on schizophreniaAMP Schizophrenia: The Partners**Government**

NIH
	FDA
	European Medicines Agency**Industry/Non-Profit**

American Psychiatric Association Foundation
	Boehringer Ingelheim
	Foundation for the NIH
	Janssen
	National Alliance on Mental Illness
	One Mind
	Otsuka
	Schizophrenia & Psychosis Action Alliance
	WellcomeResourcesAccelerating Medicines Partnership® SCHIZOPHRENIA
 Connect with Us Contact Us
      X
      Facebook
      Instagram
      YouTube
      Flickr
      More Social Media from NIH
 Footer
    NIH Home
      Virtual Tour
      En Español
      Visitor Information
      Frequently Asked Questions
      Privacy Policy
      Disclaimers
      Accessibility
      NIH Website ArchivesNondiscrimination Notice
      Freedom of Information Act
      No Fear Act
      HHS Vulnerability Disclosure
      Office of Inspector General
      USA.govNIH...Turning Discovery Into Health®
    National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892
    U.S. Department of Health and Human Services
 Back to Top